NantHealth and NantOmics Reveal a Novel AI Based Machine-Learning Digital Pathology Software for Lung Cancer by Identifying Tumor Infiltrating Killer Cells from Whole Slide Images - NantHealth

Burlingame, CA – January 27, 2020: NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in molecular analysis, today presented a novel artificial intelligence platform for aiding pathologists in image-based lung cancer subtyping at the Society for Imaging Science and Technology's International Symposium on Electronic Imaging 2020. This novel machine vision software platform accurately subtypes lung cancer pathology and achieves high concordance with analysis performed by trained medical pathologists. An initial report of the AI technology was presented at the Sixth American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC) International Joint Conference. The study entitled, "Tumor-infiltrating lymphocytes (TILs) found elevated in lung adenocarcinomas (LUAD) using automated digital pathology masks derived from deep-learning models" concluded that despite lower overall TMB (tumor mutation burden) and lymphocyte levels, there exists a subset of lung cancers with very high infiltrating lymphocyte counts. Derived from deep-learning models, together, the findings demonstrate a novel AI-based method for subtyping lung cancer pathologies which impacts treatment options for patients and improved methods of identifying tumor infiltrating white cells found elevated in lung cancer.